Sepracor appears to have almost stopped advertising for sleeping pill Lunesta, and yet sales are still rising. Sepracor spent less than $1 million on ads for the brand in 2009, but Lunesta sales ...

Back in August, BNET ragged on Sepracor for implementing a cost-cutting program that drove up its expenses and drove down its revenue. In its Q4 earnings today, the company has turned that all ...

Sepracor is stepping up its marketing spend for Lunesta in an effort to boost wavering sales and take advantage of the disappearance of anticipated sleep-aid rival Indiplon.The announcement came as ...

Sepracor investors got some depressing news today when Eli Lilly called off a deal that might have extended the patent on Prozac, one of Eli Lilly's blockbuster drugs. The announcement dragged ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., an Osaka, Japan-based pharmaceutical company, announced today that Sepracor's name will be changed to Sunovion Pharmaceuticals Inc. in the United ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Sepracor Inc. (SEPR) Q2 FY08 Earnings Call July 29, 2008 8:30 AM ETExecutivesAdrian Adams - President and CEOJonae R.